939 related articles for article (PubMed ID: 27136743)
21. The phytological future of prostate cancer staging: PSMA-PET and the dandelion theory.
Sathianathen NJ; Geurts N; Nair R; Lawrentschuk N; Murphy DG; Lamb AD
Future Oncol; 2017 Aug; 13(20):1801-1807. PubMed ID: 28762288
[TBL] [Abstract][Full Text] [Related]
22. Imaging of Prostate-Specific Membrane Antigen with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical Applications.
Rowe SP; Gorin MA; Pomper MG
Annu Rev Med; 2019 Jan; 70():461-477. PubMed ID: 30691373
[TBL] [Abstract][Full Text] [Related]
23. Integration of PSMA-targeted PET imaging into the armamentarium for detecting clinically significant prostate cancer.
Meyer AR; Joice GA; Allaf ME; Rowe SP; Gorin MA
Curr Opin Urol; 2018 Nov; 28(6):493-498. PubMed ID: 30188333
[TBL] [Abstract][Full Text] [Related]
24. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
Hofman MS; Iravani A
PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455
[TBL] [Abstract][Full Text] [Related]
25. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
Aggarwal R; Wei X; Kim W; Small EJ; Ryan CJ; Carroll P; Cooperberg M; Evans MJ; Hope T
Eur Urol Oncol; 2018 May; 1(1):78-82. PubMed ID: 31100231
[TBL] [Abstract][Full Text] [Related]
26.
Chaloupka M; Herlemann A; D'Anastasi M; Cyran CC; Ilhan H; Gratzke C; Stief CG
Urol Clin North Am; 2017 Nov; 44(4):557-563. PubMed ID: 29107272
[TBL] [Abstract][Full Text] [Related]
27. Therapy assessment in prostate cancer using choline and PSMA PET/CT.
Ceci F; Herrmann K; Hadaschik B; Castellucci P; Fanti S
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):78-83. PubMed ID: 28540419
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis.
Kim SJ; Lee SW; Ha HK
Urol Int; 2019; 102(1):27-36. PubMed ID: 30269140
[TBL] [Abstract][Full Text] [Related]
29. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.
Lütje S; Heskamp S; Cornelissen AS; Poeppel TD; van den Broek SA; Rosenbaum-Krumme S; Bockisch A; Gotthardt M; Rijpkema M; Boerman OC
Theranostics; 2015; 5(12):1388-401. PubMed ID: 26681984
[TBL] [Abstract][Full Text] [Related]
30. Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.
Yin Y; Werner RA; Higuchi T; Lapa C; Pienta KJ; Pomper MG; Gorin MA; Rowe SP
J Nucl Med; 2019 Apr; 60(4):511-516. PubMed ID: 30190303
[TBL] [Abstract][Full Text] [Related]
31. PET/CT imaging of prostate cancer in the era of small molecule prostate specific membrane antigen targeted tracers.
Vrachimis A; Ferentinos K; Demetriou E; Ioannides C; Zamboglou N
Hell J Nucl Med; 2020; 23(3):339-345. PubMed ID: 33306762
[TBL] [Abstract][Full Text] [Related]
32. Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer.
Siva S; Udovicich C; Tran B; Zargar H; Murphy DG; Hofman MS
Nat Rev Urol; 2020 Feb; 17(2):107-118. PubMed ID: 31937920
[TBL] [Abstract][Full Text] [Related]
33. Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging.
Hofman MS; Iravani A; Nzenza T; Murphy DG
Urol Clin North Am; 2018 Aug; 45(3):503-524. PubMed ID: 30031469
[TBL] [Abstract][Full Text] [Related]
34. New Targets for PET Molecular Imaging of Prostate Cancer.
Mena E; Lindenberg LM; Choyke PL
Semin Nucl Med; 2019 Jul; 49(4):326-336. PubMed ID: 31227055
[TBL] [Abstract][Full Text] [Related]
35. PSMA Ligands for PET Imaging of Prostate Cancer.
Schwarzenboeck SM; Rauscher I; Bluemel C; Fendler WP; Rowe SP; Pomper MG; Afshar-Oromieh A; Herrmann K; Eiber M
J Nucl Med; 2017 Oct; 58(10):1545-1552. PubMed ID: 28687599
[TBL] [Abstract][Full Text] [Related]
36. PET imaging in prostate cancer: focus on prostate-specific membrane antigen.
Mease RC; Foss CA; Pomper MG
Curr Top Med Chem; 2013; 13(8):951-62. PubMed ID: 23590171
[TBL] [Abstract][Full Text] [Related]
37. The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer.
Dorff TB; Fanti S; Farolfi A; Reiter RE; Sadun TY; Sartor O
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():321-330. PubMed ID: 31099673
[TBL] [Abstract][Full Text] [Related]
38. Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.
Kratochwil C; Afshar-Oromieh A; Kopka K; Haberkorn U; Giesel FL
Semin Nucl Med; 2016 Sep; 46(5):405-18. PubMed ID: 27553466
[TBL] [Abstract][Full Text] [Related]
39. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
van Leeuwen PJ; Emmett L; Ho B; Delprado W; Ting F; Nguyen Q; Stricker PD
BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581
[TBL] [Abstract][Full Text] [Related]
40. Preclinical Evaluation of
Cardinale J; Schäfer M; Benešová M; Bauder-Wüst U; Leotta K; Eder M; Neels OC; Haberkorn U; Giesel FL; Kopka K
J Nucl Med; 2017 Mar; 58(3):425-431. PubMed ID: 27789722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
